Arch Therapeutics Inc. | Income Statement
Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
0.60
0.30
-
-
1.50
5.30
Gross Income
0.60
0.30
-
-
1.50
5.30
SG&A Expense
1,744.40
4,611.40
5,460.50
6,050.80
7,301.10
7,444.40
EBIT
1,745.00
4,611.80
5,460.50
6,050.80
7,302.60
7,449.80
Unusual Expense
-
3,420.00
2,890.80
335.10
433.90
2,635.70
Non Operating Income/Expense
0.10
-
-
-
-
-
Interest Expense
108.90
111.10
377.80
276.70
52.40
-
Pretax Income
1,853.80
8,142.80
2,947.50
5,992.40
7,788.90
4,814
Consolidated Net Income
1,853.80
8,142.80
2,947.50
5,992.40
7,788.90
4,814
Net Income
1,853.80
8,142.80
2,947.50
5,992.40
7,788.90
4,814
Net Income After Extraordinaries
1,853.80
8,142.80
2,947.50
5,992.40
7,788.90
4,814
Net Income Available to Common
1,853.80
8,142.80
2,947.50
5,992.40
7,788.90
4,814
EPS (Basic)
0.09
0.12
0.04
0.05
0.05
0.03
Basic Shares Outstanding
21,366.80
67,492.80
81,394.90
121,462.90
142,722.80
152,712.70
EPS (Diluted)
0.09
0.12
0.04
0.05
0.05
0.03
Diluted Shares Outstanding
21,366.80
67,492.80
81,394.90
121,462.90
142,722.80
152,712.70
EBITDA
1,744.40
4,611.40
5,460.50
6,050.80
7,301.10
7,444.40
About Arch Therapeutics
View Profile
